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Abstract
Objectives: To determine the relationship between energy and nutrient consumption with chemosensory changes
in cancer patients under chemotherapy.
Methods: We carried out a cross-sectional study, enrolling 60 subjects. Cases were defined as patients with cancer
diagnosis after their second chemotherapy cycle (n = 30), and controls were subjects without cancer (n = 30).
Subjective changes of taste during treatment were assessed. Food consumption habits were obtained with a food
frequency questionnaire validated for Mexican population. Five different concentrations of three basic flavors
–sweet (sucrose), bitter (urea), and a novel basic taste, umami (sodium glutamate)– were used to measure
detection thresholds and recognition thresholds (RT). We determine differences between energy and nutrient
consumption in cases and controls and their association with taste DT and RT.
Results: No demographic differences were found between groups. Cases showed higher sweet DT (6.4 vs.
4.4 μmol/ml; p = 0.03) and a higher bitter RT (100 vs. 95 μmol/ml; p = 0.04) than controls. Cases with sweet DT
above the median showed significant lower daily energy (2,043 vs.1,586 kcal; p = 0.02), proteins (81.4 vs. 54 g/day;
p = 0.01), carbohydrates (246 vs.192 g/day; p = 0.05), and zinc consumption (19 vs.11 mg/day; p = 0.01)
compared to cases without sweet DT alteration. Cases with sweet DT and RT above median were associated with
lower completion of energy requirements and consequent weight loss. There was no association between
flavors DT or RT and nutrient ingestion in the control group.
Conclusion: Changes of sweet DT and bitter RT in cancer patients under chemotherapy treatment were associated
with lower energy and nutrient ingestion. Taste detection and recognition thresholds disorders could be important
factors in malnutrition development on patients with cancer under chemotherapy treatment.
Introduction
Malnutrition and weight loss are common in patients
with cancer [1], both factors could potentially affect the
response and tolerance to treatment [2,3], decrease qual-
ity of life (QOL), and associate with poor survival [4].
Multiple pathogenic mechanisms have been linked to
weight loss and malnutrition in cancer patients. Modifi-
cations in smell or taste senses could play a significant
role in the etiology of anorexia in cancer patients [5,6].
Taste disorders may affect food selection and contribute
to poor meal intake and low quality of life [7-9]. DeWys
[10] was among the first to implicate taste threshold
abnormalities in anorexia development in patients with
cancer. Specific mechanisms remain uncertain but some
studies have associated anorexia in cancer patients with
mucositis, dental disease, tumor invasion, vitamin defi-
ciencies, poor oral hygiene, bacterial, viral or fungal
oral/nasal cavity infections, postnasal drip, gastroesopha-
geal reflux and volatile compounds in inhaled air
[11-13]. Taste disorders are common in patients with
cancer under chemotherapy [14-17]. Chemotherapeutic
drugs associated with taste changes include cisplatin,
carboplatin, cyclophosphamide, doxorubicin, 5-flourour-
acil, and methotrexate [18,19]. Chemotherapy drugs
could affect other rapidly growing cells such as the taste
receptors. A variety of circulating drugs that permeate
into saliva and diffused from blood to taste receptors* Correspondence: ksanchez@medicasur.org.mx1Oncology Center Diana Laura Riojas de Colosio, Médica Sur Clinic and
Foundation, Mexico City, Mexico
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resulting in a phenomenon called venous taste change
[20].
Previous studies have reported alterations of the four
basic flavors (sweet, salty, sour and bitter) in cancer
patients [21,22]; the most common complain during
cytotoxic drugs administration occurs in bitter and
sweet flavor recognition [16]. However, there is not
enough data to determine changes in umami, a recently
described basic flavor, in chemotherapy treated cancer
patients [23-27].
This study evaluated self-perceived taste function
exam in patients with cancer diagnosis under che-
motherapy (cases) and healthy subjects (controls) to
determine differences in energy intake and taste
recognition.
Patients and Methods
We conducted a cross-sectional study in a University
hospital, oncology center of Mexico City. Our popula-
tion consisted of 60 subjects. Exclusion criteria included
history of oral/nasal cavity infections, brain disease,
acute respiratory illness, gastroesophageal reflux, central
nervous system metastasis, gastrointestinal cancer, and
head and neck cancer. Thirty subjects with a histological
diagnosis of a malignant neoplasia (breast, lung, pros-
tate, multiple myeloma and lymphoma) after their sec-
ond chemotherapy cycle were defined as cases. Thirty
patient relatives were defined as controls; they were
healthy and have no clinical history of acute and chronic
disease. Eligible patients had histological proved diagno-
sis of clinical stages II and III cancer with an Eastern
Cooperative Group performance status (ECOG) of 0 to
1. The study protocol was approved by the Institutional
Ethics Committee. All subjects provided written
informed consent.
Physical exam
Body weight was measured in light clothing and without
shoes, to the nearest 0.10 kg. Height was measured to
the nearest 0.5 cm. Body mass index (BMI) was calcu-
lated in all subjects.
Questionnaire
Subjects completed all information on demographic
data: age, gender, alcohol consumption, and smoking
habits. Other medications used in cases prior to this
study were identified to discard those that might affect
taste detection or appetite.
Dietary history questionnaire
Patients were requested to complete a questionnaire of
symptoms related to appetite loss and changes in flavor
detection. Nutrients intake was evaluated using the
“SNUT” program. This food frequency questionnaire
(FFQ) was developed and validated for Mexican popula-
tion by the National Institute of Public Health [28]
SNUT is composed of a matrix listing 116 food items
and 10 frequencies of consumption with specified size
portion; the program also included information concern-
ing the frequency of ingestion and the brand of vitamin
supplements. SNUT software calculate daily intake of:
calories, proteins, carbohydrates, saturated, polyunsatu-
rated and monounsaturated fat; vitamins, and zinc. We
calculated individual total metabolic rate (30 kcal per
kilogram body weight per day) and protein requirements
(1.0 gram per kilogram per day) in all patients, and
compared this result with calories and protein consump-
tion. Patients with cancer diagnosis (cases) were classi-
fied as subjects that completed their calculated needs
and subjects who did not. Each of this group classifica-
tion was compared looking for differences in taste per-
ception detection threshold and recognition threshold
(RT).
Taste evaluations
Five concentrations of the three main flavor substances
were dissolved in distilled water, including sucrose (3.5-
15.5 μmol/ml), urea (91-115 μmol/ml), and sodium glu-
tamate (0.3-2.7 μmol/ml). Solutions were freshly pre-
pared every week by serial dilutions and stored at 4-5°C.
Before testing, 5-ml samples in 30-ml plastic cups were
brought to room temperature (24 ± 2°C); the presenta-
tion order of the five concentrations was randomized
before giving them to study subjects. The patients were
scheduled for study testing 4 hours after eating or
smoking. The patient’s mouth was rinsed with a sip of
distilled water prior to testing each 5-ml sample.
Data analysis
For descriptive purposes continuous variables were sum-
marized as median and standard deviation and categori-
cal variables comprised proportions. Interferential
comparisons were carried out by Student t and Mann-
Whitney U test according to distribution (normal and
non-normal) determined by the Kolmogorov-Smirnov
test. Chi square test and Fisher’s Exact test were utilized
to assess significance among categorical variables. When
the control and test group were matched, we use the
Wilcoxon Signed Ranks test and express the result like
z (Mean Rank differences). Statical significance was
determined as p < 0.05 with a two-sided test. All statisti-
cal analyses were carried out with SPSS/PC v. 15.0 pro-
gram software (SPSS, Inc., Chicago, IL, USA).
Results
Sixty subjects were included in the study: 30 cancer
patients after their second chemotherapy cycle and 30
controls. There were no significant differences in
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gender, age, energy intake, and nutrient consumption
between groups. Controls had higher BMI compared to
cases (Table 1). Cases had higher percentage of Taste
loss (43.3% vs 10% p = 0.04), and taste distortion (33.3
vs 10%, p = 0.05) (Table 2).
We found significant differences in DT of sweet flavor
(p = 0.05) and bitter RT (p = 0.04) between cases and
controls (Table 3). When the control and test group
were matched, the sweet DT presented statistical signifi-
cance (p = 0.027). Patients under chemotherapy
required increased concentrations of taste flavors in
order to recognize bitter- and sweet- flavor. We corre-
lated the upper and lower values from the median of
the two significant threshold values (sweet DT and bit-
ter RT, since umami did not show significant differences
between groups) with the median of energy and nutri-
ents intake. Cases with higher than the median sweet
DT presented significant lower calorie consumption per
day (1,450 vs. 1,970 kcal/day), as well as lower nutrient
consumption: protein (53 vs. 74 g/day), carbohydrate
(167 vs. 240 g/day), and zinc (9.6 vs. 17 mg/day) (Table
4). Patients with values higher than the median for bitter
RT had significantly lower calorie (1,493 vs. 2,124 kcal),
protein (52 vs. 83 g/day), carbohydrate (182 vs. 254 g/day),
and fat (62 vs. 87 g/day) consumption (Table 5). No
differences were found in detection or recognition thresh-
olds and nutrient intake between the control group.
The proportion of patients that were not able to com-
plete their daily energy requirements was higher in
those with values of sweet DT, sweet RT, and bitter RT
above the median compared to patients with normal
taste thresholds (Table 6). Lower daily caloric intake
was found in patients with values above the median of
sweet DT (-632 ± 361 vs -32 ± 162 kcal/day, p = 0.05),
sweet RT (-428 ± 2.58 vs 14.7 ± 8.2 kcal/day, p = 0.06)
and bitter RT (-487.4 vs 66 kcal/day, p = 0.031). The
percentage of subjects with weight loss was higher in
patients with bitter RT above the median (100% vs 67%,
p = 0.03). Umami taste thresholds differences were not
associated with changes in energy and nutrient
consumption.
Discussion
Abnormalities in taste recognition have been reported in
patients with cancer [29-34]. In our study, cancer
patients reported more subjective chemosensory com-
plaints than controls. In addition, these differences
could not be attributed to age or gender differences
because demographic characteristics and performance
status were similar in both groups. The most frequent
complaint was taste loss and a tendency toward bad
taste perception. Similar results were found in other stu-
dies: in a study made by Hutton et al. [35], 86% of
patients with cancer reported some degree of subjective
chemosensory abnormalities. In another study that
included 284 cancer patients, the most frequently che-
mosensory complaints were dry mouth, decreased appe-
tite, nausea, and vomiting [18].
Berberetche et al. [36] reported 110 cancer patients
with significantly higher taste thresholds, in the four
basic flavors than controls, detected by electrotaste test.
Our study found significant differences in bitter RT and
sweet DT between cancer patients under chemotherapy
treatment and controls. Other studies have found similar
results, Carson et al. [29] reported slight increases in sour
DT and bitter RT during the early chemotherapy treat-
ment period and normalization of the sweet RT after 2
weeks of treatment. In a study that included 30 Lung
cancer patients and controls, differences in recognition
thresholds for sweet taste were assessed [30]. Trant et al.
[37] reported that 22 patients under chemotherapy were
less likely to display a distinct preference for any of the
five concentrations of sucrose, particularly high levels,
than those not on chemotherapy.
In this study, no differences were found in umami
taste RT between groups. Subjects were not able to
describe the flavor; this is why some subjects had no
detection or recognition threshold at any concentration.
Table 1 Descriptive statistics in cancer patients in the











56.0 ± 15 49.4 ± 11 0.07
BMI 21.6 ± 1.4 25.1 ± 0.9 0.02
Calories/day 1,830 ± 732 1,621 ± 717 0.26
Proteins (g/day) 69 ± 42 57.4 ± 26 0.21
Carbohydrates (g/day) 221 ± 88 202.5 ± 105 0.46
Fat (g/day) 75.9 ± 33 63 ± 36 0.15
Zinc (mg/day) 15.3 ± 7.9 16.7 ± 10 0.56
Alcohol (g/day) 1.06 ± 0.6 1.18 ± 0.9 0.82
Caffeine (g/day) 59 ± 66 146.8 ± 230 0.61*
Smoking 3% 16.6% 0.19
BMI = body mass index
*Mann-Whitney U test. SD, Standard deviation
Table 2 Subjective chemosensory complaints in cancer
patients in the second chemotherapy cycle and controls.
Subjective symptoms Cases Controls p *
Taste loss 13 (43.3%) 3 (10%) 0.04
Taste distortion 10 (33.3%) 3 (10%) 0.05
Bad taste in the mouth 17 (56.6%) 7 (23.3%) 0.06
* Chi squared test
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There is only one study in the literature that determined
umami DT in cancer patients, this study included 30
patients with head and neck cancer under radiotherapy;
significantly impaired DT of umami taste was revealed
at 30 Gy detected by electrotaste test [24]. No studies of
umami taste detection or recognition thresholds con-
ducted in patients under chemotherapy were found in
the literature.
During ingestion and digestion processes, sensory
information is transmitted to the brain and integrated
with past food memory and the hunger/satiety condi-
tions. If the meal is experienced an unsatisfactory event,
such as abdominal pain after eating, it is recorded in the
memory as unpleasant (aversive) food [27]. Taste disor-
ders are unpleasant experiences; it is well known that
taste signals affect food preference and food intake,
playing an important role in anorexia, weight loss and
malnutrition disorders in patients with cancer, however,
there are few studies determining the impact of taste
abnormalities and food intake in patients with cancer.
Calories and nutrient intake did not show statistical
differences between cases and controls in our studied
population, this could be due to a good performance
status in all included patients (ECOG 0-1) and the
exclusion of individuals with gastrointestinal cancer.
The comparison between patients with upper sweet
DT and bitter RT values above the median versus those
with values below the median, showed a significant dif-
ference for low calorie and nutriment intake in cancer
patients (cases) with higher sweet DT and bitter RT
values. (Tables 4, and 5). These findings agree with
other reports and confirm that taste disorders not only
reduce the patient’s quality of life (QOL), but they may
also lead to insufficient eating habits affecting dietary
intake and nutritional status [15,38,39]. Hutton et al
[35] reported lower energy intake (by 900-1,000 kcal/
day), higher rates of weight loss, and lower QOL scores
in patients with severe chemotherapy-associated chemo-
sensory distortions. Other study including 72 patients
under chemotherapy, reported changes in consumption
of sweet and salty foods with 82% of the patients avoid-
ing food with such flavors [40].
Zinc deficiency has been associated with taste disor-
ders in some but not all reported studies [41-46]. A pos-
sible explanation has been described: Drugs that cause
hypogeusia have a sulfhydryl group in their structures;
this component is known to bind and chelate heavy
metal ions like zinc [16]. In the present study, zinc con-
sumption was not significantly different between cases
and controls. However, cases with higher sweet RT
Table 3 Median of Detection and recognition thresholds in cancer patients in the second chemotherapy cycle and
controls
Threshold Cases (μmol/ml) Controls (μmol/ml) p * Mean rank differences (z) p**
Sweet DT 6.4 ± 4 4.4 ± 1.7 0.05 2.22 0.027
Sweet RT 8.9 ± 4 8.1 ± 5.8 0.58 0.98 0.325
Bitter DT 92 ± 5.7 89.3 ± 16 0.30 0.85 0.398
Bitter RT 100 ± 8 95 ± 7 0.04 0.63 0.527
Umami DT 1.1 ± 0.8 0.84 ± 0.6 0.19 0.04 0.96
Umami RT 2.1 ± 0.7 1.9 ± 0.7 0.3 0.10 0.919
μmol/ml = micromol/millimeter
*Mann-Whitney U test
** Wilcoxon Signed Ranks test
Table 4 Median of sweet detection threshold vs. diet
consumption in cancer patients in the second
chemotherapy cycle
Nutrient ≥ 6.4 μmol/ml <6.4 μmol/ml p*
Calories per Day 1,450 ± 833 1,970 ± 658 0.05
Proteins (g/day) 53 ± 32 74 ± 45 0.02
Carbohydrates
(g/day)
167 ± 81 240 ± 84 0.04
Fat (g/day) 57 ± 33 82 ± 31 0.08




* Mann-Whitney U test
Table 5 Median of Bitter recognition threshold vs.
diet consumption in cancer patients in the second
chemotherapy cycle
Nutrient ≥ 100 μmol/ml <100 μmol/ml p*
Calories per
Day
1,493 ± 452 2,124 ± 812 0.01
Proteins (g/day) 52 ± 17 83 ± 53 0.04
Carbohydrates
(g/day)
182 ± 58 254 ± 98 0.02
Fat (g/day) 62 ± 22 87 ± 38 0.03




* Mann-Whitney U test
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exhibited significantly less zinc consumption than
patients with lower thresholds; these data might suggest
some relationship between high sweet RT and low zinc
intake.
More measures are needed to prevent taste distortions
in patients with cancer. Clinicians play an important
role in the detection, education, and referring of patients
who experience taste disorders. Nutritional management
of individuals with chemosensory disorders requires a
complete clinical and nutritional evaluation with appro-
priate dietary-intake measurements and expert nutri-
tional counseling.
Methodological weaknesses of this research include:
Variability in cancer types and chemotherapy drugs
used; and the absence of basal taste disorder evaluation
before chemotherapy treatment, and for establishing a
causal association between chemotherapy and taste dis-
orders. Continuing research is required to develop better
understanding of the nature, frequency, severity, and
duration of taste alterations and their significance in
food consumption and malnutrition in those patients
with cancer under chemotherapy.
Conclusions
Cancer patients under chemotherapy have higher sweet
detection threshold and higher bitter recognition thresh-
old compared to patients without cancer. These
abnormalities are associated with decreased calorie, pro-
tein, carbohydrate, fat and zinc intake; there were also a
high proportion of patients that were not able to com-
plete their daily energy requirements, resulting in weight
loss. Taste disorders could signify an important factor in
malnutrition and wasting of patients with cancer.
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